Tinea gladiatorum: Wrestling's emerging foe

Sports Medicine

Volumn 29, Issue 6, 2000, Pages 439-447

  Kohl, Thomas D ^a,b   Lisney, Mary ^a  

^a READING HOSPITAL AND MEDICAL CENTER   (United States)

^b NONE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CICLOPIROX; CICLOPIROXOLAMINE; CLOTRIMAZOLE; ECONAZOLE; GRISEOFULVIN; HALOPROGIN; ITRACONAZOLE; KETOCONAZOLE; MICONAZOLE; NAFTIFINE; OXICONAZOLE; SULCONAZOLE; TERBINAFINE; TOLNAFTATE;

CLINICAL FEATURE; DISEASE TRANSMISSION; DRUG EFFICACY; HUMAN; PATIENT COMPLIANCE; REVIEW; RISK FACTOR; TINEA; TINEA GLADIATORUM; TRICHOPHYTON TONSURANS; WRESTLING;

EID: 0034043460     PISSN: 01121642     EISSN: None     Source Type: Journal    
DOI: 10.2165/00007256-200029060-00006     Document Type: Review

References (34)

1. 1. Cohen BA, Schmidt C. Tinea gladiatorum [letter). N Engl J Med 1992; 327: 820
2. 2. Beller M, Gessner BD. An outbreak of tinea corporis gladiatorum on a high school wrestling team. J Am Acad Dermatol 1994; 31 (2 Pt 1): 197-201
3. 3. Stiller MJ, Klein WP, Dorman RI, et al. Tinea corporis gladiatorum: an epidemic of Trichophyton tonsurans in student wrestlers. J Am Acad Dermatol 1992; 27 (4): 632-3
4. 4. Werninghaus K. Tinea corporis in wrestlers [letter]. J Am Acad Dermatol 1993; 28: 1022-3
5. 5. Kohl TD, Martin D, Berger MS. Comparison of topical and oral treatment for tinea gladiatorum. Clin J Sport Med 1999; 9 (3): 161-6
6. 6. Hradil E, Hersle K, Nordin P, et al. An epidemic of tinea corporis caused by Trichophyton tonsurans among wrestlers in Sweden. Acta Derm Venereol 1995; 75: 305-6
7. 7. Hazen PG, Weil ML. Itraconazole in the prevention and management of dermatophytosis in competitive wrestlers. J Am Acad Dermatol 1997; 36 (3 Pt 1): 481-2
8. 8. Dienst WL, Dightman L, Dworkin MS, et al. Pinning down skin infections. Physician Sports Med 1997; 25 (12): 45-56
9. 9. Odom R. Pathophysiology of dermatophyte infections. J Am Acad Dermatol 1993; 28 (5): S2-7
10. 10. Frisk A, Heilborn H, Melon B. An epidemic of tinea corporis caused by Trichophyton tonsurans among wrestlers in Sweden. Acta Derm Venereol 1966; 46: 453-6
11. 11. Kern ME, Blevins KS. Medical mycology: a self-instructional text. Philadelphia (PA): F.A. Davis Company, 1997
12. 12. Kemna ME, Elewski BE. A U.S. survey of superficial fungal diseases. J Am Acad Dermatol 1996; 35 (4): 539-42
13. 13. Hay RJ. Dermatophytosis and other superficial mycoses. In: Mandell GL, Douglas RG, Bennet JE, editors. Principles and practice of infectious diseases. 3rd ed. New York (NY): Churchill Livingstone, 1990: 2017-27
14. 14. Knudsen EA. Experimental dermatophyte infection: the extent of fungal invasion. Acta Derm Venereol 1989; 69: 247-9
15. 15. Hebert AA, Head ES, MacDonald EM. Tinea capitis caused by Trichophyton tonsurans. Pediatr Dermatol 1985; 2: 219-23
16. 16. Cohn MS. Superficial fungal infections: topical and oral treatment of common types. Postgrad Med 1992; 91 (2): 239-44
17. 17. Bergus GR, Johnson JS. Superficial tinea infections. Am Fam Physician 1993; 48 (2): 259-68
18. 18. Haldane DJ, Robart E. A comparison of calcofluor white, potassium hydroxide, and culture in the laboratory diagnosis of superficial fungal infections. Diagn Microbiol Infect Dis 1990; 13: 337-9
19. 19. Drake LA, et al. Guidelines of care for superficial mycotic infections of the skin: tinea corporis, tinea faciei, tinea manuum, and tinea pedis. J Am Acad Dermatol 1996; 34: 282-6
20. 20. Fromtling RA. Overview of medically important antifungal azole derivatives. Clin Microhiol Rev 1988; I: 187-217
21. 21. Smith EB. Topical antifungal drugs in the treatment of tinea pedis,tinea cruris, and tinea corporis. J Am Acad Dermatol 1993; 28: S24-8
22. 22. Gupta AK, Sauder DN, Shear NH. Antifungal agents: an overview. Part II. J Am Acad Dermatol 1994; 30: 911-33
23. 23. Friedlander SF. The evolving role of itraconazole, fluconazole, and terbenifine in the treatment of tinea capitis. Pediatr Infect Dis J 1999; 18 (2): 205-10
24. 24. Cauwenbergh G, Degreef H, Heykants J, et al. Pharmacokinetic profile of orally administered itraconazole in human skin. J Am Acad Dermatol 1988; 18: 263-8
25. 25. Willemsen M, DeDonecker P, Willems J, et al. Posttreatment itraconazole levels in the nail. J Am Acad Dermatol 1992; 26: 731-5
26. 26. Faergemann J, Laufen H. Levels of fluconazole in serum, stratum corneum, epidermis-dermis (without stratum corneum) and eccrine sweat. Clin Exp Dermatol 1993; 18 (2): 102-6
27. 27. Haneke E. Fluconazole levels in human epidermis and blister fluid. Br J Dermatol 1990: 123: 273-7
28. 28. Faergemann J, Zehender H, Jones T, et al. Terbenifine levels in serum,stratum corneum, dermis-epidermis (without stratum corneum) and eccrine sweat. Acta Derm Venereol 1991; 71 (4): 322-6
29. 29. Bourland A, Lachapelle JM, Aussems J, et al. Double-blind comparison of itraconazole and griseofulvin in the treatment of tinea corporis and tinea cruris. Int J Dermatol 1989; 28: 410-2
30. 30. Hernanz ADP, Gomez SL, Lastra FG, et al. A comparative double-blind study of terbenifine and griseofulvin in tinea corporis and tinea cruris. Clin Exp Dermatol 1990; 15: 210-6
31. 31. Roberts WO. Specific problems and pearls in wrestling. American College of Sports Medicine Team Physician II Course; 1999 Feb 24-28; San Antonio, 14
32. 32. Goodman RA, Thacker SB, Solomon SL, et al. Infectious disease in competitive sports. JAMA 1994; 271 (11): 862-7
33. 33. Sevier TL. Infectious diseases in athletes. Med Clin North Am 1993; 78 (2): 389-412
34. 34. Scheinberg RS. Stopping skin assailants: fungi, yeasts, and viruses. Physician Sports Med 1994; 22: 33-9